Prothena Corporation plc (PRTA)

21,34 -0,66 (-3,00%) Börsenschluss: 04:00PM EDT

Prothena Corporation plc

77 Sir John Rogerson’s Quay
Block C Grand Canal Docklands
Dublin D02 VK60
Ireland
353 1 236 2500
https://www.prothena.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 173

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Gene G. Kinney Ph.D.	President, CEO & Director	1M	1,97M	1969
Mr. Tran B. Nguyen M.B.A.	CFO & Chief Strategy Officer	830,14k	5,92M	1974
Mr. Brandon S. Smith	Chief Operating Officer	757,79k	1,07M	1975
Ms. Carol D. Karp	Chief Regulatory Officer	701,48k	2,1M	1953
Dr. Hideki Garren M.D., Ph.D.	Chief Medical Officer	808,71k	1,09M	1965
Ms. Karin L. Walker CPA	Chief Accounting Officer & Controller	N/A	N/A	1963
Dr. Wagner M. Zago	Chief Scientific Officer	478,79k	N/A	1973
Mr. Mark C. Johnson C.F.A.	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Michael J. Malecek	Chief Legal Officer	588,25k	N/A	1966
Mr. David A. Ford	Chief People Officer	N/A	N/A	1970

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Corporate Governance

Prothena Corporation plcs ISS Governance QualityScore, Stand 1. Mai 2024, lautet 4. Die grundlegenden Scores sind Audit: 7, Vorstand: 4, Shareholderrechte: 3, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.